Bob Azelby, Eliem CEO
April 25, 2022 08:57 AM EDT
Startups
R&D

'Re­sults are un­am­bigu­ous': Eliem's lead pro­gram fails and share price halves be­fore open­ing bell

Kyle LaHucik

Senior Reporter

When Eliem Ther­a­peu­tics launched last March, CSO Va­lerie Moris­set told End­points News that up­on be­ing ap­proached about mak­ing a leap to the biotech, she had …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times